Immunopharmacology | Pharmacology | GPAT Mock Test

Welcome to the GPAT Mock Test on Immunopharmacology, focusing specifically on Immunostimulants and Immunosuppressants. This quiz is designed to help you assess your understanding of crucial drugs that modulate the immune system. You will face 25 multiple-choice questions covering mechanisms of action, clinical applications, and major adverse effects of key agents used in organ transplantation, autoimmune diseases, and cancer therapy. This targeted practice will sharpen your knowledge for the GPAT examination. After submitting your answers, you’ll receive your score and see a detailed breakdown of correct and incorrect responses. You can also download a PDF copy of all questions and their correct answers for future revision. Good luck!

1. Cyclosporine exerts its immunosuppressive effect by binding to which intracellular protein, leading to the inhibition of calcineurin?

2. Which of the following is the primary mechanism of action of Tacrolimus?

3. A major dose-limiting toxicity common to both Cyclosporine and Tacrolimus is:

4. Sirolimus (Rapamycin) works by inhibiting which of the following key signaling proteins in T-lymphocyte proliferation?

5. Mycophenolate Mofetil is an immunosuppressant that selectively inhibits the proliferation of lymphocytes by blocking which enzyme?

6. Azathioprine is a prodrug that is converted in the body to its active metabolite, which is:

7. Basiliximab is a monoclonal antibody used to prevent acute organ rejection. What is its specific molecular target?

8. Rituximab is a chimeric monoclonal antibody that causes depletion of B-lymphocytes by targeting which surface antigen?

9. A cancer patient undergoing chemotherapy develops severe neutropenia. Which immunostimulant would be most appropriate to administer?

10. Aldesleukin, used in the treatment of metastatic renal cell carcinoma and melanoma, is a recombinant form of which cytokine?

11. A serious and potentially fatal adverse effect associated with high-dose Aldesleukin therapy is:

12. Interferon-α is approved for the treatment of various conditions, including:

13. Which agent is administered intravesically (into the bladder) as an immunostimulant to treat superficial bladder cancer?

14. Thalidomide, known for its teratogenicity, has been repurposed as an immunomodulatory agent for treating:

15. Patients should be screened for deficiency in which enzyme before starting Azathioprine therapy to avoid severe myelosuppression?

16. Due to its potent anti-proliferative effects, Sirolimus is commonly used to coat coronary stents to prevent:

17. Which of the following is a polyclonal antibody preparation derived from animals, used for the treatment of acute transplant rejection?

18. The broad immunosuppressive and anti-inflammatory effects of corticosteroids are primarily mediated by:

19. Levamisole, an anthelmintic drug, was historically used in combination with 5-FU for colon cancer due to its purported _____ properties.

20. Which immunosuppressant is more specific for lymphocytes because they rely heavily on the de novo pathway of purine synthesis, which this drug inhibits?

21. Sargramostim is the recombinant form of which hematopoietic growth factor that stimulates a broader range of white blood cells than G-CSF?

22. Although both are calcineurin inhibitors, a key difference between Tacrolimus and Cyclosporine is that:

23. Gingival hyperplasia, hirsutism, and hypertension are characteristic adverse effects of which immunosuppressant drug?

24. Infliximab is a monoclonal antibody that acts as an immunosuppressant by targeting and neutralizing:

25. The two primary clinical indications for the use of immunosuppressive drugs are: